FYR Diagnostics

Missoula, United States Founded: 2016 • Age: 10 yrs
In-vitro diagnostic tests for disease detection are provided.

About FYR Diagnostics

FYR Diagnostics is a company based in Missoula (United States) founded in 2016.. FYR Diagnostics has raised $8 million across 4 funding rounds from investors including HHS and America’s Seed Fund. FYR Diagnostics offers products and services including Liquid Biopsy Solutions and Sequencing Services. FYR Diagnostics operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.

  • Headquarter Missoula, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $8 M (USD)

    in 4 rounds

  • Latest Funding Round
    $8 M (USD), Series A

    Aug 02, 2024

  • Investors
    HHS

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of FYR Diagnostics

FYR Diagnostics offers a comprehensive portfolio of products and services, including Liquid Biopsy Solutions and Sequencing Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Develops tools using EVs for detecting disease biomarkers in healthcare.

Offers high-quality next-generation sequencing for clinical and research needs.

People of FYR Diagnostics
Headcount 10-50
Employee Profiles 6
Employee Profiles
People
Chris Booth
Chief Executive Officer
People
Katie Havranek
Director of Research and Development
People
Tre Blohm, MA, MDT(AMT)
Junior research scientist
People
Brian Conway   MBA
VP of Operations

Unlock access to complete

Funding Insights of FYR Diagnostics

FYR Diagnostics has successfully raised a total of $8M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $8 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series A — $8.0M
  • First Round

    (01 Sep 2019)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2024 Amount Series A - FYR Diagnostics Valuation

investors

Aug, 2021 Amount Grant - FYR Diagnostics Valuation

investors

HHS
Dec, 2020 Amount Grant - FYR Diagnostics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in FYR Diagnostics

FYR Diagnostics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and America’s Seed Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital fund backed by the US Government
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by FYR Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - FYR Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Fyr Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of FYR Diagnostics

FYR Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Solutions for biomarker discovery and diagnostic testing are provided.
domain founded_year HQ Location
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
domain founded_year HQ Location
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
domain founded_year HQ Location
Proteomics platform developed for early cancer and neurological disease detection.
domain founded_year HQ Location
Novel cancer drugs are developed using synthetic lethality screening.
domain founded_year HQ Location
NeoPhore is focused on cancer neoantigen evolution therapies.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Fyr Diagnostics

Frequently Asked Questions about FYR Diagnostics

When was FYR Diagnostics founded?

FYR Diagnostics was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is FYR Diagnostics located?

FYR Diagnostics is headquartered in Missoula, United States. It is registered at Missoula, Montana, United States.

Is FYR Diagnostics a funded company?

FYR Diagnostics is a funded company, having raised a total of $8M across 4 funding rounds to date. The company's 1st funding round was a Grant of $256K, raised on Sep 01, 2019.

What does FYR Diagnostics do?

FYR Diagnostics was founded in 2016 in Missoula, United States, within the healthcare and diagnostics sector. In-vitro diagnostic tests are offered for disease detection in humans and agriculture. A portfolio of biomarker detection technologies is developed, emphasizing nucleic acid amplification methods. These technologies support accelerated prediction, diagnosis, and management of diseases through laboratory-based operations.

Who are the top competitors of FYR Diagnostics?

FYR Diagnostics's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.

What products or services does FYR Diagnostics offer?

FYR Diagnostics offers Liquid Biopsy Solutions and Sequencing Services.

Who are FYR Diagnostics's investors?

FYR Diagnostics has 2 investors. Key investors include HHS, and America’s Seed Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available